GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cessatech AS (XSAT:CESSA) » Definitions » Debt-to-EBITDA

Cessatech AS (XSAT:CESSA) Debt-to-EBITDA : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Cessatech AS Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cessatech AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Cessatech AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Cessatech AS's annualized EBITDA for the quarter that ended in Mar. 2025 was kr-22.44 Mil. Cessatech AS's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cessatech AS's Debt-to-EBITDA or its related term are showing as below:

XSAT:CESSA's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.15
* Ranked among companies with meaningful Debt-to-EBITDA only.

Cessatech AS Debt-to-EBITDA Historical Data

The historical data trend for Cessatech AS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cessatech AS Debt-to-EBITDA Chart

Cessatech AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
N/A - - - -

Cessatech AS Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cessatech AS's Debt-to-EBITDA

For the Biotechnology subindustry, Cessatech AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cessatech AS's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cessatech AS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cessatech AS's Debt-to-EBITDA falls into.


;
;

Cessatech AS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cessatech AS's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -19.053
=0.00

Cessatech AS's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -22.44
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Cessatech AS  (XSAT:CESSA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cessatech AS Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cessatech AS's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cessatech AS Business Description

Traded in Other Exchanges
Address
Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.

Cessatech AS Headlines

No Headlines